SEC FORM 4

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Fok Manson

(Last)

(First)

(Middle)

C/O ATHENEX, INC.

1001 MAIN STREET, SUITE 600

(Street)

BUFFALO

14203

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Athenex, Inc. [ ATNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Rule 10b5-1(c) Transaction Indication

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/21/2023		A		5,747	A	$1.305⁽¹⁾	110,675⁽²⁾	D
Common Stock								33,944⁽²⁾	I⁽³⁾⁽⁴⁾	By Avalon Biomedical (Management) Limited⁽³⁾⁽⁴⁾
Common Stock								5,360⁽²⁾⁽⁵⁾	I⁽³⁾⁽⁴⁾⁽⁵⁾	By Avalon Polytom (HK) Limited⁽³⁾⁽⁴⁾⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$91⁽⁶⁾							05/13/2014	05/13/2023	Common Stock	2,400⁽⁶⁾		2,400⁽⁶⁾	D
Stock Option (Right to Buy)	$91⁽⁶⁾							10/11/2015	10/11/2023	Common Stock	1,000⁽⁶⁾		1,000⁽⁶⁾	D
Stock Option (Right to Buy)	$91⁽⁶⁾							06/12/2016	06/12/2024	Common Stock	2,000⁽⁶⁾		2,000⁽⁶⁾	D
Stock Option (Right to Buy)	$150⁽⁶⁾							05/18/2016	05/18/2025	Common Stock	2,400⁽⁶⁾		2,400⁽⁶⁾	D
Stock Option (Right to Buy)	$180⁽⁶⁾							10/17/2017	10/17/2025	Common Stock	2,400⁽⁶⁾		2,400⁽⁶⁾	D
Stock Option (Right to Buy)	$220⁽⁶⁾							06/13/2021	06/13/2027	Common Stock	1,350⁽⁶⁾		1,350⁽⁶⁾	D
Stock Option (Right to Buy)	$180⁽⁶⁾							07/17/2018	07/17/2025	Common Stock	2,746⁽⁶⁾		2,746⁽⁶⁾	I⁽³⁾⁽⁴⁾	By Avalon Biomedical (Management) Limited⁽³⁾⁽⁴⁾
Stock Option (Right to Buy)	$346⁽⁶⁾							03/27/2022	03/27/2028	Common Stock	750⁽⁶⁾		750⁽⁶⁾	D
Stock Option (Right to Buy)	$263.4⁽⁶⁾							02/28/2023	02/28/2029	Common Stock	500⁽⁶⁾		500⁽⁶⁾	D
Stock Option (Right to Buy)	$249⁽⁶⁾							⁽⁷⁾	06/05/2030	Common Stock	500⁽⁶⁾		500⁽⁶⁾	D
Stock Option (Right to Buy)	$76⁽⁶⁾							08/03/2022	08/03/2031	Common Stock	313⁽⁶⁾		313⁽⁶⁾	D
Stock Option (Right to Buy)	$9.14⁽⁶⁾							⁽⁸⁾	06/28/2032	Common Stock	625⁽⁶⁾		625⁽⁶⁾	D

Explanation of Responses:

1. Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.

2. As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock.

3. Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Mason Fok, M.B., B.S. ("Dr. Fok"), together with his spouse, own all of the outstanding interests in Sino Glory Developments Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Fok serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.

4. Dr. Fok disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Fok is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

5. These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.

6. This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023.

7. This option vests in four equal annual installments beginning on June 5, 2021.

8. This option vests on June 28, 2023.

Remarks:

	/s/ Staci Holquist, Attorney-in-Fact	04/24/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 4 filed by Fok Manson